Patents by Inventor Pablo MARTIN SANZ

Pablo MARTIN SANZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10617699
    Abstract: The present invention relates to an orally administrable pharmaceutical dosage form for use in the prevention and/or treatment of a cardiovascular disease which includes (a) acetylsalicylic acid as a first active agent and (b) HMG-CoA reductase inhibitor as a second active agent. The HMG-CoA reductase inhibitor is selected from atorvastatin and rosuvastatin and salts thereof. The present invention is formulated in (a) two or more single separate coated dosage units in which the coating includes one or more water-soluble polymer and no more than 0 to 5% by weight of the coating of water-insoluble or enteric polymer, and in which the dosage units include 8 to 12 mg/cm2 coating and show an immediate release profile; and (b) one or more single separate coated dosage units.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: April 14, 2020
    Assignees: FERRER INTERNACIONAL, S.A., FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III
    Inventors: Pablo Martin Sanz, Javier Urbano Hurtado
  • Publication number: 20160106763
    Abstract: The present invention relates to a pharmaceutical composition which includes a HMG-CoA reductase inhibitor, in particular, a statin and acetylsalicylic acid in a manner to minimize interaction of acetylsalicylic acid with the statin, for use in the prevention or treatment of cardiovascular diseases.
    Type: Application
    Filed: June 5, 2014
    Publication date: April 21, 2016
    Applicants: FERRER INTERNACIONAL, S.A., FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III
    Inventors: Pablo MARTIN SANZ, Javier URBANO HURTADO